Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

SEHK:3700
SEHK:3700Interactive Media and Services

Asian Penny Stocks To Watch In May 2026

Amidst a backdrop of geopolitical tensions and central banks holding interest rates steady, Asian markets are navigating a complex landscape shaped by energy price fluctuations and evolving economic policies. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials.
ENXTBR:COFB
ENXTBR:COFBHealth Care REITs

A Look At Cofinimmo (ENXTBR:COFB) Valuation After Q1 Earnings Reveal Higher Sales And Lower Net Income

Earnings snapshot and why it matters now Cofinimmo (ENXTBR:COFB) has just reported first quarter 2026 results, with sales of €87.31 million compared with €86.81 million a year earlier, while net income came in at €53.51 million versus €64.26 million. This mix of slightly higher sales and lower profitability is giving investors fresh numbers to reassess the stock, especially following the recent share price moves over the past month and over the past three months. See our latest analysis for...
NYSE:LDOS
NYSE:LDOSProfessional Services

Leidos Holdings (LDOS) Net Margin Near 8.2% Tests Slower Earnings Growth Narratives

Leidos Holdings (LDOS) opened 2026 with Q1 revenue of US$4.4b and basic EPS of US$2.60, alongside trailing 12 month revenue of US$17.3b and EPS of US$11.13 that sit against a 8.2% net margin, up from 7.9% a year earlier. Over the past year, earnings growth of 6.1% has run below the five year average of 18.1%. This puts more weight on how investors read the balance between steady profit generation and the current margin profile. Overall, the latest numbers point to a business where...
NasdaqCM:NUTX
NasdaqCM:NUTXHealthcare

Nutex Health (NUTX) Is Up 5.1% After Strong Q1 Results And New Buyback Plan - What's Changed

Nutex Health reported past first-quarter 2026 results on April 30, with revenue of US$216.49 million and net income of US$46.81 million, lifting both basic and diluted earnings per share from continuing operations versus a year earlier. Alongside these results, the company announced a second US$25.00 million share repurchase program and a shift toward directly developing new hospital facilities, signaling a material change in how it funds and expands its footprint. We’ll now examine how...
ENXTPA:BNP
ENXTPA:BNPBanks

How Investors Are Reacting To BNP Paribas (ENXTPA:BNP) Strong Q1 Earnings And MREL Capital Buffer

In the first quarter of 2026, BNP Paribas reported net interest income of €14,056 million and net income of €3,217 million, and confirmed that its total MREL ratio of 29.7% sits well above newly updated ACPR regulatory thresholds. This combination of earnings growth and a sizeable capital buffer under the revised MREL regime underlines the group’s capacity to absorb shocks while continuing to support clients and regulatory initiatives like outcome-linked bonds and loan-market...
NYSE:AU
NYSE:AUMetals and Mining

Is It Too Late To Consider AngloGold Ashanti (NYSE:AU) After 136% One Year Surge?

Wondering whether AngloGold Ashanti at around US$98.60 is still offering value after a strong run, or if most of the easy gains are already behind it. The stock has been volatile recently, with a 9.0% return over the last 7 days, a 2.8% decline over 30 days, a 15.2% return year to date, and a 136.0% return over the last year, alongside very large multi year gains of around 3x over 3 years and nearly 4x over 5 years. Recent coverage has focused on AngloGold Ashanti's position within the...
NYSE:FERG
NYSE:FERGTrade Distributors

Ferguson (FERG) Q1 2026 Margin Gains Test Bullish Earnings Narratives

Ferguson Enterprises Q1 2026 headline numbers Ferguson Enterprises (FERG) opened fiscal Q1 2026 with revenue of about US$7.5b and basic EPS of US$2.13, setting a clear marker for how the business is starting the new financial year. The company has seen quarterly revenue move from roughly US$7.2b in Q1 2025 to about US$7.5b in Q4 2025 and then US$7.5b in Q1 2026. Basic EPS has shifted from US$1.74 to US$1.99 and then US$2.13 over the same periods, giving investors a view on how earnings are...
NYSE:JBTM
NYSE:JBTMMachinery

JBT Marel (JBTM) Quarterly Profit Of US$53.1m Tests Bearish Loss-Narrative

JBT Marel (JBTM) has just put fresh numbers on the table for Q1 2026, coming off Q4 2025 revenue of about US$1.0 billion and basic EPS of US$1.02, against a trailing twelve month picture that includes a basic EPS loss of US$0.96 on US$3.8 billion of revenue. Over the past few quarters, the company has seen quarterly revenue move from US$453.8 million in Q3 2024 to US$854.1 million in Q1 2025 and then to roughly US$1.0 billion by Q4 2025. EPS swung from US$1.19 in Q3 2024 to a loss of US$3.35...
OM:BOL
OM:BOLMetals and Mining

Is It Too Late To Consider Boliden (OM:BOL) After Its 81% One Year Surge?

If you are wondering whether Boliden's share price still offers value after its strong run, or if you are late to the party, this article walks through what the current price might imply. The stock most recently closed at SEK 525.4, with returns of 9.7% over 7 days, 4.5% over 30 days, 0.8% year to date, 81.1% over 1 year, 54.9% over 3 years and 77.0% over 5 years. Recent coverage has focused on Boliden's position within the broader materials and mining sector and how shifts in sentiment...
SEHK:9999
SEHK:9999Entertainment

Assessing NetEase (SEHK:9999) Valuation After Recent Share Price Rebound And Longer Term Returns

NetEase stock in focus after recent share performance NetEase (SEHK:9999) has come back into focus for investors after recent share performance, with the stock returning 3.7% over the past week and roughly 3.8% over the past month. This short term move sits alongside a year to date return of a 20.7% decline and a past 3 months return of a 5.8% decline, prompting closer attention to how the company’s fundamentals line up with current pricing. See our latest analysis for NetEase. Recent trading...
NYSE:NRG
NYSE:NRGElectric Utilities

Is It Time To Revisit NRG Energy (NRG) After Its Strong Five Year Share Price Gain

With NRG Energy last closing at US$150.64, this article looks at whether the stock is still priced for opportunity or already reflects most of its story, and what that may mean for you as an investor. The stock has returned 1.1% over the last 7 days and 0.6% over the last 30 days, with a year-to-date decline of 9.3% and a 28.4% return over the last year, alongside a very large gain over 5 years. Recent coverage has focused on NRG Energy's position within the US utilities sector and how its...
NYSE:VG
NYSE:VGOil and Gas

Venture Global’s CP2 Progress And New Deals Reshape Risk Reward Profile

Venture Global (NYSE:VG) has taken a final investment decision on Phase 2 of its CP2 LNG project and secured project financing, reducing construction and cash flow risks. The company reached a commercial settlement with Edison related to Calcasieu Pass arbitration, addressing an outstanding legal dispute. Venture Global signed a new binding LNG purchase agreement with Vitol for five years starting in 2026. For investors watching US LNG developers, Venture Global sits at the intersection of...
NYSE:FND
NYSE:FNDSpecialty Retail

Is It Time To Reconsider Floor & Decor (FND) After A 30% One Year Share Price Drop

If you are wondering whether Floor & Decor Holdings at around US$51 a share is attractively priced or a potential value trap, the starting point is understanding how the current market price lines up against different measures of value. The stock has recently moved 7.0% over the last week and 3.3% over the last month, while the year to date return sits at a 19.0% decline and the 1 year return at a 30.5% decline, which may catch the eye of investors weighing up risk and recovery...
SEHK:3933
SEHK:3933Pharmaceuticals

Assessing United Laboratories International Holdings (SEHK:3933) Valuation After Dupilumab Biosimilar Trial Approval

Clinical trial approval and what it means for investors United Laboratories International Holdings (SEHK:3933) has drawn fresh attention after regulators in China approved the clinical trial application for its dupilumab biosimilar targeting atopic dermatitis, a step that highlights progress in its autoimmune pipeline. See our latest analysis for United Laboratories International Holdings. The share price has recently picked up, with a 1-day share price return of 2.77% taking the stock to...
ASX:QBE
ASX:QBEInsurance

Will Climate-Risk Disclosure Push and US Legal Dispute Change QBE Insurance Group's (ASX:QBE) Narrative

Australian Ethical Investment Ltd. previously filed a shareholder resolution pressing QBE Insurance Group for fuller disclosure and regular assessment of climate-related risk exposure, while QBE urged investors to vote it down, arguing the proposal misinterprets its insurance model and portfolio management. Separately, QBE Insurance Corporation has taken a US$16.00 million-plus construction receivables dispute to a Manhattan federal court, highlighting how legal outcomes can influence how...
NYSE:IT
NYSE:ITIT

Gartner (IT) Margin Reset To 11.2% Reinforces Bearish Profitability Narratives

Gartner (IT) has put fresh numbers on the board for Q1 2026, reporting revenue of US$1.5b and basic EPS of US$3.19 off net income of US$222.3m, setting the tone for how you might think about the rest of the year. Over recent quarters the company has seen revenue move between US$1.5b and US$1.8b, while quarterly EPS has ranged from US$0.47 to US$5.14, providing a clear view of how earnings power has fluctuated into this latest print. With trailing net margins now sitting well below last year’s...
NYSE:SMR
NYSE:SMRElectrical

Is NuScale Power (SMR) Pricing In Nuclear Policy Support Despite Mixed Long Term Returns

If you are wondering whether NuScale Power's current share price reflects its true worth, this article will help you size up the stock using several valuation tools. The stock recently closed at US$11.87, with returns of 0.4% over 7 days, 16.9% over 30 days, a 27.2% decline year to date, a 32.8% decline over 1 year, 47.6% over 3 years and 19.8% over 5 years. This gives you a wide range of outcomes to think about. Recent coverage has focused on NuScale Power's role in nuclear energy...
NasdaqGS:GH
NasdaqGS:GHHealthcare

FDA Approval Adds New Catalyst To Guardant Health Valuation Story

Guardant Health’s Guardant360 CDx liquid biopsy has received FDA approval as a companion diagnostic for VEPPANU, a therapy for ER+/HER2- advanced breast cancer with ESR1 mutations. This is the third ESR1 companion diagnostic approval tied to Guardant360 CDx, further linking the test to targeted breast cancer treatments. The new approval broadens the clinical use of Guardant360 CDx and deepens Guardant Health’s ties with pharmaceutical partners. For investors tracking Guardant Health...
NasdaqGS:ALKS
NasdaqGS:ALKSBiotechs

Alkermes (ALKS) Margin Compression Tests Bullish Earnings Growth Narratives Ahead Of Q1 2026

Alkermes Q1 2026 earnings: setting the stage Alkermes (ALKS) heads into Q1 2026 following its Q4 2025 report, where revenue was US$384.5 million and basic EPS came in at US$0.30, with net income excluding extra items of US$49.3 million. Over recent quarters, the company has reported revenue of US$429.99 million in Q4 2024, US$390.7 million in Q2 2025, and US$394.2 million in Q3 2025. Quarterly basic EPS over that period was US$0.90 in Q4 2024, US$0.50 in Q3 2025, and US$0.30 in Q4 2025. These...
NYSE:SDRL
NYSE:SDRLEnergy Services

Assessing Seadrill (SDRL) Valuation After Recent Share Price Swings And Ongoing Turnaround Prospects

Seadrill stock snapshot after recent performance Seadrill (SDRL) has drawn fresh attention after recent trading, with the stock last closing at US$48.90 and showing mixed short term returns, including a 0.9% decline over the past day and 1.8% decline over the past week. See our latest analysis for Seadrill. While Seadrill’s 1 day and 7 day share price returns are slightly negative, the 30 day and 90 day share price returns of 7.2% and 23.5%, together with a 1 year total shareholder return of...
ENXTPA:GLE
ENXTPA:GLEBanks

Assessing Société Générale (ENXTPA:GLE) Valuation After First Quarter 2026 Earnings Upgrade

Société Générale Société anonyme (ENXTPA:GLE) has released first quarter 2026 results, reporting net interest income of €7,106 million and net income of €1,696 million, both higher than the prior year period. See our latest analysis for Société Générale Société anonyme. The 1 day share price return of 5.55% following the earnings release comes after a mixed few months, with a 30 day share price return of 8.97% but a 90 day share price decline of 5.69%. Even so, total shareholder return over 1...
NYSE:RVTY
NYSE:RVTYLife Sciences

Revvity (RVTY) Net Margin Deterioration Tests Bullish Recovery Narratives Ahead Of Q1 2026

Revvity Q1 2026 earnings snapshot Revvity (RVTY) has just put fresh numbers on the table, with recent quarters showing revenue between US$664.8 million and US$772.1 million and basic EPS ranging from US$0.35 to US$0.85 as the company heads into its Q1 2026 update. Over the past year, revenue has been recorded from US$684.0 million in Q3 2024 up to US$772.1 million in Q4 2025, while basic EPS prints in that stretch run from US$0.35 to US$0.85, giving investors a clear view of how the top line...